小剂量尿激酶联合蚓激酶治疗急性进展性脑梗死临床的研究.docVIP

小剂量尿激酶联合蚓激酶治疗急性进展性脑梗死临床的研究 　　【摘要】 目的：研究小剂量尿激酶联合蚓激酶治疗急性进展性脑梗死的临床效果。方法：将恩平市人民医院2015年2月-2016年6月收治的60例急性脑梗死患者按照随机数字表法分为对照组与治疗组，每组各30例。对照组采用蚓激酶治疗，治疗组采用小剂量尿激酶联合蚓激酶治疗。比较两组患者神经功能缺损程度、日常生活能力、治疗效果。结果：治疗后两组患者NIHSS、ADL评分均降低，但对照组治疗后NIHSS、ADL评分（18.3±4.7）分、（13.3±1.8）分均高于治疗组（11.6±3.5）分、（11.4±1.6）分，且对照组治疗总有效率（73.3%）低于治疗组（93.3%），比较差异均有统计学意义（P0.05）。结论：给予急性进展性脑梗死患者小剂量尿激酶联合蚓激酶治疗效果显著，能有效改善患者神经功能，提高生活质量。 　　【关键词】 小剂量尿激酶； 蚓激酶； 急性进展性脑梗死 　　【Abstract】 Objective：To study the clinical effect on low dose of Urokinase combined with Lumbrokinase in the treatment of acute progressive cerebral infarction （APCI）.Method：60 APCI patients admitted into the Enping People’s Hospital from February 2015 to June 2016 were randomly divided into control group of 30 cases which took lumbrokinase and treatment group of 30 cases which took low dose of Urokinase combined with Lumbrokinase.The degree of nervous functional defect，activity of daily living （ADL） and curative effect of two groups were compared.Result：After treatment，the NIHSS and ADL scores of two groups decreased，while the control group of NIHSS and ADL score were respectively （18.3±4.7） scores and （13.3±1.8） scores higher than the treatment group of （11.6±3.5） scores and （11.4±1.6） scores；the total effective rate of control group was 73.6% lower than treatment group of 93.3%，the differences were statistically significant（P0.05）.Conclusion：Low dose of Urokinase combined with Lumbrokinase for treating APCI patients have significant curative effect，which can effectively improve patients’ neurologic function and increase living of quality. 　　【Key words】 Low dose of urokinase； Lumbrokinase； Acute progressive cerebral infarction 　　First-author’s address：The People’s Hospital of Enping City，Enping 529400，China 　　doi：10.3969/j.issn.1674-4985.2017.01.008 　　急性进展性脑梗死病情发展较快，病情严重，治愈难度大，发生率、致残率与致死率?^高。患者临床表现为阶梯型加重的局限性脑缺血、神经功能损伤[1-2]。研究显示，脑梗死发生、发展与动脉硬化有关，血小板是动脉粥样硬化、血栓形成的主要环节，可造成动脉管腔狭窄，减缓血流速度，导致血管阻塞，逐渐扩大脑梗死面积，加重病情[3-4]。尿激酶与蚓激酶作为临床治疗脑梗死的常用药物，可将纤维蛋白分解，溶解血栓，但临床研